Metabolic Health
CAPTAIN-T2D Interim Data: 75%+ of Hard-to-Control T2D Patients Show Elevated Cortisol
The findings reinforce cortisol modulation as a credible clinical target — and raise formulation questions for the adap…
Metabolic Health 9 stories
Metabolic Health
NIS4 Biomarker Panel Enters Direct-to-Consumer Lab Market via Labcorp
The move positions non-invasive MASH screening alongside liver-health nutraceuticals at a pivotal moment for the fatty …
Metabolic Health
Tegoprubart Islet Transplant Trial Posts Updated T1D Data
Immunosuppression mechanism under scrutiny as transplant tolerance data edges closer to clinical relevance for metaboli…
Metabolic Health
HDV-Insulin Lispro Cuts Hypoglycemia in Phase 2b Type 1 Diabetes Trial
Hepatocyte-directed vesicle technology positions the delivery platform at the intersection of pharma and advanced nutra…
Metabolic Health
Survodutide Phase III Cuts Visceral Fat 34%, Liver Fat 63% in Obesity Trials
Results published simultaneously in NEJM and Nature Medicine signal a new mechanistic benchmark for metabolic-health fo…
Metabolic Health
Ribupatide Phase Data Surfaces at ADA 2026 via Hengrui-Kailera
As the metabolic health ingredient space watches GLP-1 mimetic botanicals gain shelf space, pharma-grade peptide data c…
Metabolic Health
Icovamenib Posts HbA1c, C-Peptide Gains in Type 1 Diabetes Trial
Biomea Fusion also flags muscle-preservation and fat-reduction signals, positioning the menin inhibitor as a potential …
Metabolic Health
Rivus Pharma's Oral GLP-1 Candidate Shows Muscle-Preserving Effects in Preclinical Data
As GLP-1 weight-loss agents reshape the metabolic health market, lean-mass retention emerges as a key functional differ…
Metabolic Health
Non-Invasive Glucose Monitoring Market Eyes 25.6% CAGR Through 2034
A tenfold market expansion over ten years is reshaping how brands position glycemic-support ingredients and finished fo…